Tredaptive launched in UK
This article was originally published in Scrip
Merck Sharp & Dohme (Merck & Co) has launched its dyslipidaemia treatment Tredaptive (nicotinic acid 1,000mg plus laropiprant 20mg) tablets in the UK. The product is indicated for patients with combined mixed dyslipidaemia or primary hypercholesterolaemia. It should be used in combination with a statin when statin monotherapy is inadequate in lowering cholesterol, or as monotherapy in patients intolerant of statins or for whom statin therapy is inappropriate. It costs £16.73 for 28 tablets and £33.46 for 56 tablets. The European Commission approved a centralised marketing authorisation for Tredaptive in July last year. It is already launched in Ireland.
You may also be interested in...
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.